Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hassan joins B&L board: Former Schering-Plough CEO Fred Hassan brings extensive experience in corporate and trade group leadership to the board of Rochester, N.Y.-based vision care product firm Bausch & Lomb, according to a Nov. 12 release. Hassan became Schering's CEO in 2003, leading the firm as it revived its allergy business following the first-in-category OTC switch of the Claritin (loratadine) allergy drug in December 2002, and continued there until Merck acquired the firm in a deal that closed Nov. 3. He also was CEO at Pharmacia Corp. from 2001 to 2003, when it was acquired by Pfizer. Hassan has held senior posts in the pharmaceutical industry since 1972 and has headed the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers Associations

You may also be interested in...



FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues

FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues

FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel